Early Hydrogen-Oxygen Gas Mixture Inhalation in Patients with Aneurysmal Subarachnoid Hemorrhage (HOMA): study protocol for a randomized controlled trial

• Published in: Current controlled trials in cardiovascular medicine 2024-06, Vol.25 (1), p.377-8, Article 377
• Main Authors: Lin, Fa, Li, Runting, Chen, Yu, Yang, Jun, Wang, Ke, Jia, Yitong, Han, Heze, Hao, Qiang, Shi, Guangzhi, Wang, Shuo, Zhao, Yuanli, Chen, Xiaolin
• Format: Article
• Language: English
• Subjects: Administration, Inhalation; Adult; Aged; Aneurysmal subarachnoid hemorrhage; Aneurysms; Blood pressure; Brain; Brain Ischemia - drug therapy; Brain Ischemia - prevention & control; Cerebral vasospasm; China; Clinical outcomes; Clinical trials; Cognitive ability; Delayed cerebral ischemia; Female; Flow velocity; Health aspects; Hemorrhage; Hospitals; Humans; Hydrogen; Hydrogen - administration & dosage; Hydrogen–oxygen gas; Injuries; Ischemia; Male; Medical ethics; Medical imaging; Medical research; Medicine, Experimental; Middle Aged; Mortality; Nimodipine; Oxidative stress; Oxygen - administration & dosage; Oxygen Inhalation Therapy - adverse effects; Oxygen saturation; Patients; Prognosis; Prospective Studies; Randomized controlled trial; Randomized Controlled Trials as Topic; Respiratory therapy; Stroke; Stroke (Disease); Study Protocol; Subarachnoid hemorrhage; Subarachnoid Hemorrhage - drug therapy; Time Factors; Traumatic brain injury; Treatment Outcome; Vasospasm, Intracranial - drug therapy; Vasospasm, Intracranial - etiology; Vasospasm, Intracranial - prevention & control; Young Adult
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-024-08231-5

Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening neurosurgical emergency with a high mortality rate. Delayed cerebral ischemia (DCI) and cerebral vasospasm (CVS) are delayed products of early brain injury (EBI), which may constitute the principal determinant of an unfavorable patient prognosis. Consequently, the mitigation of DCI and CVS assumes paramount significance in the pursuit of enhanced patient outcomes. However, except for oral nimodipine, there is no effective therapy available in the current guideline. Hence, the exigency arises to proffer novel treatment paradigms. The diversity of hydrogen therapeutic targets has been largely reported in basic research, unveiling its latent capacity to ameliorate EBI in aSAH patients. Early Hydrogen-Oxygen Gas Mixture Inhalation in Patients with Aneurysmal Subarachnoid Hemorrhage (HOMA), a single-center, prospective, open-labeled, randomized controlled clinical trial, endeavors to evaluate the efficacy and safety of hydrogen-oxygen gas mixture inhalation therapy in aSAH patients. A cohort of 206 patients will be randomized to either hydrogen-oxygen gas mixture inhalation group (8 h per day, 3 L/min, hydrogen concentration of 67%, oxygen concentration of 33%) or oxygen inhalation group (8 h per day, 3 L/min, oxygen concentration of 33%) within 72 h after aSAH and treated for 7 days in the ICU ward. The primary outcomes are the incidence of DCI and CVS during hospitalization. The HOMA aims to evaluate the effectiveness of hydrogen-oxygen gas mixture inhalation therapy in preventing DCI or CVS and improving outcomes in aSAH patients. Notably, this is the first large-scale trial of hydrogen therapy in aSAH patients. Given that the Chinese population represents a significant portion of the global population and the increasing incidence of stroke due to aging, optimizing patient care is vital. Given the current challenges in aSAH patient outcomes, initiating more prospective clinical trials is essential. Recent research has shown hydrogen's therapeutic potential, aligning with EBI in aSAH, driving our exploration of hydrogen therapy's mechanisms in post-aneurysm rupture damage. The protocol for the HOMA study was approved by the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University (KY 2022-020-02). All results of the present study will be published in peer-reviewed journals and presented at relevant conferences. ClinicalTrials.gov NCT05282836. Registered on March 16, 2022.